AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 SEP 5 - (NewsRx.com & NewsRx.net) -- FemmePharma, Inc.'s, lead drug for the treatment of endometriosis is currently being studied in a nationwide phase II clinical trial with one center in the Chicago area.
FemmePharma, based in Wayne, Pennsylvania, a Philadelphia suburb, was founded in 1996 by CEO Gerianne Tringali DiPiano. DiPiano approached investors with her plan to form a pharmaceutical company devoted to women's unmet health needs.
According to DiPiano, "Drug companies assume that their products have equal applicability to men and women, despite inherent physiological differences between the sexes." DiPiano estimates the women's healthcare segment to be a $35 billion market.
FemmePharma's patented platform technology will allow drugs to be given intravaginally, which should reduce the amount of drugs getting into the bloodstream and hopefully the side effects caused by other drug delivery approaches. Instead of being distributed throughout the body, intravaginal administration should allow FemmePharma's drugs to enter directly into the pelvic and reproductive organs and be absorbed by the affected areas.
FemmePharma has plans to study their technology in conditions including endometriosis, urinary incontinence and cervical cancer, as well as a variety of other diseases and disorders.
From 1996 through 2000, FemmePharma had been funded by DiPiano and an National Institutes of Health grant. In November of 2000, the company received a ...